This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

SciClone Pharmaceuticals (Holdings) 과거 수익 실적

과거 기준 확인 6/6

SciClone Pharmaceuticals (Holdings)은 연평균 11.2%의 비율로 수입이 증가해 온 반면, Pharmaceuticals 산업은 수입이 증가했으며, 연간 5.7%였습니다. 매출은 연평균 14.8%의 비율로 증가했습니다. SciClone Pharmaceuticals (Holdings)의 자기자본이익률은 34.4%이고 순이익률은 35.6%입니다.

주요 정보

11.2%

수익 성장률

7.1%

EPS 성장률

Pharmaceuticals 산업 성장	5.6%
매출 성장률	14.8%
자기자본 수익률	34.4%
순이익	35.6%
최근 수익 업데이트	31 Dec 2023

최근 과거 실적 업데이트

Recent updates

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Apr 02

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Dec 14

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Jun 19

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

May 31

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Feb 17

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Dec 02

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Oct 04

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Jul 27

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Jun 02

수익 및 비용 분석

SciClone Pharmaceuticals (Holdings) 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.

수익 및 매출 내역

SEHK:6600 수익, 비용 및 수입 (CNY Millions )
날짜	수익	수익	G+A 비용	R&D 비용
31 Dec 23	3,156	1,122	870	171
30 Sep 23	3,017	1,038	839	159
30 Jun 23	2,878	953	808	147
31 Mar 23	2,814	904	781	135
31 Dec 22	2,750	855	753	124
30 Sep 22	2,706	844	738	134
30 Jun 22	2,662	833	724	145
31 Mar 22	2,590	878	726	140
31 Dec 21	2,518	923	729	134
30 Sep 21	2,259	837	742	114
30 Jun 21	2,089	779	753	85
31 Mar 21	2,004	766	703	80
31 Dec 20	1,919	754	653	75
30 Sep 20	2,001	817	615	77
31 Dec 19	1,708	615	579	88
31 Dec 18	1,409	535	533	77
31 Dec 17	1,213	20	728	83
30 Jun 17	1,166	294	586	96
31 Mar 17	1,146	258	587	111
31 Dec 16	1,112	213	591	105
30 Sep 16	1,060	246	544	88
30 Jun 16	1,072	257	550	72
31 Mar 16	1,034	183	515	82
31 Dec 15	1,021	191	509	80
30 Sep 15	991	130	488	129
30 Jun 15	913	102	458	124
31 Mar 15	879	186	442	88
31 Dec 14	836	156	426	90
30 Sep 14	774	133	429	29
30 Jun 14	790	140	467	28
31 Mar 14	770	68	499	57
31 Dec 13	769	66	510	49
30 Sep 13	780	78	541	35

양질의 수익: 6600 은 높은 수익을 보유하고 있습니다.

이익 마진 증가: 6600 의 현재 순이익 이익률 (35.6%) 작년보다 높습니다 (31.1%).

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

수익추이: 6600 의 수입은 지난 5년 동안 매년 11.2% 씩 증가했습니다.

성장 가속화: 지난 1년간 6600 의 수익 증가율( 31.2% )은 연간 평균( 11.2% 초과합니다. ).

수익 대 산업: 지난 1년간 6600 수익 증가율( 31.2% )은 Pharmaceuticals 업계 9.4% 초과했습니다.

This company listing is no longer active

SciClone Pharmaceuticals (Holdings) 과거 수익 실적

과거 기준 확인 6/6

주요 정보

최근 과거 실적 업데이트

Full year 2023 earnings: EPS and revenues exceed analyst expectations

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

Recent updates

SciClone Pharmaceuticals (Holdings) Limited Announces Retirement of Wang Haixia as Non-Executive Director

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 35% Price Boost Is Out Of Tune With Earnings

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited, Annual General Meeting, Jun 18, 2024

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Sciclone Pharmaceuticals (Holdings) Limited Announces Executive Changes

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

Investor sentiment improves as stock rises 21%

Investor sentiment improves as stock rises 20%

SciClone Pharmaceuticals (Holdings) Limited Announces Phase III Clinical Trial of Vaborem® Completed Subject Enrollment in China

Here's Why We Think SciClone Pharmaceuticals (Holdings) (HKG:6600) Might Deserve Your Attention Today

Investor sentiment improves as stock rises 15%

First half 2023 earnings released: EPS: CN¥1.00 (vs CN¥0.79 in 1H 2022)

SciClone Pharmaceuticals (Holdings) Limited to Report First Half, 2023 Results on Aug 17, 2023

SciClone Pharmaceuticals (Holdings) Limited Announces First Subject Dosed in Phase III Clinical Trial of Vaborem in China

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Upcoming Dividend Will Be Larger Than Last Year's

SciClone Pharmaceuticals (Holdings) Limited Approves a Final Dividend for the Year Ended December 31, 2022

Upcoming dividend of HK$0.39 per share at 3.7% yield

Sciclone Pharmaceuticals (Holdings) Limited Announces Retirement of SHI Cen as Non-Executive Director

Full year 2022 earnings: EPS and revenues miss analyst expectations

Estimating The Fair Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited Announces Acceptance of Investigational New Drug Application for Vaborem by Center for Drug Evaluation of the China National Medical Products Administration

SciClone Pharmaceuticals (Holdings) Limited Appoints Lin Shirley Yi-Hsien as Member of the Audit Committee

Sciclone Pharmaceuticals (Holdings) Limited Announces Resignation of Ms. Li Quan as Non-Executive Director and A Member of the Audit Committee of the Board

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of Biologics License Application of Danyelza (Naxitamab) for Patients with Relapsed or Refractory High-Risk Neuroblastoma in China

Investor sentiment improved over the past week

Insider recently sold HK$218m worth of stock

Less than half of directors are independent

Insider recently sold HK$62m worth of stock

EpicentRx Announces Start of Dosing in China for Global Phase 3 Clinical Trial REPLATINUM (NCT05566041) with Partner SciClone Pharmaceuticals

SciClone Pharmaceuticals (Holdings) Limited Announces First Patient Has Been Dosed in China in RRx-001 Phase III Clinical Trial for the Third Line and Beyond Small Cell Lung Cancer

First half 2022 earnings released: EPS: CN¥0.79 (vs CN¥0.98 in 1H 2021)

SciClone Pharmaceuticals (Holdings) Limited to Report Q2, 2022 Results on Aug 18, 2022

SciClone Pharmaceuticals (Holdings) Limited Announces NMPA Approval of IND of Danyelza (Naxitamab) and GM-CSF in Combination with Irinotecan and Temozolomide in Patients with High-Risk Neuroblastoma with Primary Refractory Disease or in First Relapse

SciClone Pharmaceuticals (Holdings) Limited Appoints MAO Li as Chief Medical Officer

Sciclone Pharmaceuticals (Holdings) Limited Approves Final Dividend for the Year Ended December 31, 2021

Less than half of directors are independent

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2021 Results on Mar 24, 2022

Calculating The Intrinsic Value Of SciClone Pharmaceuticals (Holdings) Limited (HKG:6600)

We Think You Should Be Aware Of Some Concerning Factors In SciClone Pharmaceuticals (Holdings)'s (HKG:6600) Earnings

Investor sentiment improved over the past week

SciClone Pharmaceuticals (Holdings) Limited's (HKG:6600) 25% Dip In Price Shows Sentiment Is Matching Earnings

Investor sentiment deteriorated over the past week

Non-Executive Director Xiaozhuo Wang has left the company

An Intrinsic Calculation For SciClone Pharmaceuticals (Holdings) Limited (HKG:6600) Suggests It's 45% Undervalued

Full year 2020 earnings released: EPS CN¥1.38 (vs CN¥1.13 in FY 2019)

SciClone Pharmaceuticals (Holdings) Limited to Report Fiscal Year 2020 Results on Mar 25, 2021

SciClone Pharmaceuticals (Holdings) Limited has completed an IPO in the amount of HKD 2.180509 billion.

수익 및 비용 분석

수익 및 매출 내역

잉여현금흐름 대 수익 분석

과거 수익 성장 분석

자기자본 수익률

자산 수익률

고용 자본 수익률

과거 성과가 우수한 기업 찾기